Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldfarb

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 6, 2000
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivoY Guo, A A Higazi, A Arakelian, et al.
Scandinavian Journal of Immunology|September 14, 2007
Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environmentP Albertsson, P H Basse, K Edsparr, et al.
In Vivo (Athens, Greece)|April 11, 2000
A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicinR H Goldfarb, R Koelemij, K A Muirhead, et al.
In Vitro Cellular & Developmental Biology. Animal|September 1, 1995
Morphologic, immunologic, biochemical, and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19W C Welch, R S Morrison, J L Gross, et al.
In Vivo (Athens, Greece)|December 28, 2000
Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cellsU Nannmark, M E Hokland, R Agger, et al.
European Journal of Applied Physiology|July 29, 2008
Resistance exercise effects on blood glutathione status and plasma protein carbonyls: influence of partial vascular occlusionA H Goldfarb, R S Garten, P D M Chee, et al.
International Journal of Oncology|May 14, 2011
A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivoLuca Rastelli, Maria Luisa Valentino, Melissa Corso Minderman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancerJ Baselga, A Manikhas, J Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2014
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancerJ Baselga, A Manikhas, J Cortés, et al.
Brain Research. Brain Research Reviews|February 1, 1997
The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactionsB S McEwen, C A Biron, K W Brunson, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 6, 2000
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivoY Guo, A A Higazi, A Arakelian, et al.
Scandinavian Journal of Immunology|September 14, 2007
Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environmentP Albertsson, P H Basse, K Edsparr, et al.
In Vivo (Athens, Greece)|April 11, 2000
A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicinR H Goldfarb, R Koelemij, K A Muirhead, et al.
In Vitro Cellular & Developmental Biology. Animal|September 1, 1995
Morphologic, immunologic, biochemical, and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19W C Welch, R S Morrison, J L Gross, et al.
In Vivo (Athens, Greece)|December 28, 2000
Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cellsU Nannmark, M E Hokland, R Agger, et al.
European Journal of Applied Physiology|July 29, 2008
Resistance exercise effects on blood glutathione status and plasma protein carbonyls: influence of partial vascular occlusionA H Goldfarb, R S Garten, P D M Chee, et al.
International Journal of Oncology|May 14, 2011
A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivoLuca Rastelli, Maria Luisa Valentino, Melissa Corso Minderman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancerJ Baselga, A Manikhas, J Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2014
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancerJ Baselga, A Manikhas, J Cortés, et al.
Brain Research. Brain Research Reviews|February 1, 1997
The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactionsB S McEwen, C A Biron, K W Brunson, et al.
Pageof 19